RT Journal Article
SR Electronic
T1 Low-Cost Manually Assembled Open Source Reader for Isothermal Pathogen Detection from Saliva using RT-LAMP: SARS-CoV-2 Use Case
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.19.20215319
DO 10.1101/2020.10.19.20215319
A1 Bramley, John C.
A1 Waligorski, Jason E.
A1 Kremitzki, Colin L.
A1 Liebeskind, Mariel J.
A1 Yenkin, Alex L.
A1 Xu, Xinyuan E.
A1 Lalli, Matthew A.
A1 O’Halloran, Jane A.
A1 Mudd, Philip A.
A1 House, Stacey L.
A1 Mitra, Robi D.
A1 Milbrandt, Jeffrey D.
A1 Buchser, William J.
YR 2020
UL http://medrxiv.org/content/early/2020/10/21/2020.10.19.20215319.abstract
AB Distributed “Point-of-Care” or “at-Home” testing is an important component for a complete suite of testing solutions. This manuscript describes the construction and operation of a platform technology designed to meet this need. The ongoing COVID-19 pandemic will be used as the proof-of-concept for the efficacy and deployment of this platform. The technology outlined consists of a one-pot, reverse-transcription loop-mediated isothermal amplification (RT-LAMP) chemistry coupled with a low-cost and user-assembled reader using saliva as input. This platform is readily adapted to a wide range of pathogens due to the genetic basis of the reaction. A complete guide to the construction of the reader as well as the production of the reaction chemistry are provided here. Additionally, analytical limit of detection data and the results from saliva testing of SARS-CoV-2, are presented. The platform technology outlined here demonstrates a rapid, distributed, molecular point-of-care solution for pathogen detection using crude sample input.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThese studies were supported by donations to the WUSM COVID Research fund, the Department of Genetics and the McDonnell Genome Institute. We thank Barnes-Jewish Hospital, the Institute of Clinical and Translational Sciences (ICTS), and the Tissue Procurement Core, which provided saliva samples.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WU350, IRB#202003085All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll source code and schematics associated with manuscripts have been made available https://gitlab.com/buchserlab/rgd